ライフサイエンスコーパス: dual antiplatelet therapy

1 ibitor monotherapy compared with traditional dual antiplatelet therapy.

2 us ticagrelor plus ASA following 3 months of dual antiplatelet therapy.

3 ompared with aspirin alone or short duration dual antiplatelet therapy.

4 9,644 participants to different durations of dual antiplatelet therapy.

5 ive bare-metal stents followed by 1 month of dual antiplatelet therapy.

6 et activation and aggregation in patients on dual antiplatelet therapy.

7 All patients received 1 month of dual antiplatelet therapy.

8 nd points when used with a 1-month course of dual antiplatelet therapy.

9 ost common reason for premature cessation of dual antiplatelet therapy.

10 ave a higher risk of bleeding from prolonged dual antiplatelet therapy.

11 among smokers observed in trials evaluating dual antiplatelet therapy.

12 on in clinical practice, requiring prolonged dual antiplatelet therapy.

13 high risk for bleeding if they also receive dual antiplatelet therapy.

14 en in patients with early discontinuation of dual antiplatelet therapy.

15 independently correlated with high RPR after dual antiplatelet therapy.

16 heparin remain unknown in an era of routine dual antiplatelet therapy.

17 as observed only in patients not adhering to dual antiplatelet therapy.

18 trial has proved this in patients receiving dual antiplatelet therapy.

19 n-negative patients were planned for 1-month dual antiplatelet therapy.

20 associated with premature discontinuation of dual antiplatelet therapy.

21 are at-risk for premature discontinuation of dual antiplatelet therapy.

22 nts after PCI occurred in patients receiving dual antiplatelet therapy.

23 e on ticagrelor monotherapy after 1 month of dual antiplatelet therapy.

24 12-inhibitor monotherapy and 981 to continue dual antiplatelet therapy.

25 a-blocker treatment, and a neutral effect of dual antiplatelet therapy.

26 ted stent (DCS) or a BMS followed by 1-month dual antiplatelet therapy.

27 tensin receptor blockers, beta-blockers, and dual antiplatelet therapy.

28 different risks and benefits with prolonged dual antiplatelet therapy.

29 ing a feasible approach for patients needing dual antiplatelet therapy.

30 s 2 (40%) did not receive standard post-TAVI dual-antiplatelet therapy.

31 thrombosis, and thus the need for prolonged dual-antiplatelet therapy.

32 bolytic status in 300 ACS patients receiving dual-antiplatelet therapy.

33 or clopidogrel, 0.17 (95% CI, 0.04-0.76) for dual antiplatelet therapy, 0.48 (95% CI, 0.22-1.04) for

34 risk of major bleeding by 40% compared with dual antiplatelet therapy (1.97% versus 3.13%; hazard ra

35 r bleeding were 1.13 (95% CI, 1.06-1.19) for dual antiplatelet therapy, 1.82 (95% CI, 1.76-1.89) for

36 of major hemorrhage was almost doubled with dual antiplatelet therapy (105 hemorrhages, 2.1% per yea

37 cantly reduced with aspirin and clopidogrel (dual antiplatelet therapy) (125 strokes; rate, 2.5% per

38 which occurred mainly within the 21 days of dual antiplatelet therapy (200 cases, 3.1%).

39 ight [4%] of 224) than among those receiving dual antiplatelet therapy (31 [15%] of 208; p<0.0001); N

40 increased among patients assigned to receive dual antiplatelet therapy (77 deaths in the group receiv

41 C) plus aspirin (48.3%), DOAC alone (22.6%), dual antiplatelet therapy (8.1%), warfarin plus aspirin

42 was particularly high in patients receiving dual antiplatelet therapy (adjusted HR, 5.21; 95% CI, 1.

43 The benefit and need for prolonged dual antiplatelet therapy after bioresorbable scaffold i

44 olled trial, compared 30 versus 12 months of dual antiplatelet therapy after coronary stenting.

45 In the debate about the duration of dual antiplatelet therapy after drug-eluting stent impla

46 commendation ("may be considered") to extend dual antiplatelet therapy after drug-eluting stent impla

47 recommendation is for at least 12 months of dual antiplatelet therapy after implantation of a drug-e

48 gh risk for bleeding who received 1 month of dual antiplatelet therapy after PCI, the use of biodegra

49 or outcomes of HBR patients receiving 30-day dual antiplatelet therapy after percutaneous coronary in

50 Approximately 10% of patients who receive dual antiplatelet therapy after percutaneous coronary in

51 HBR inclusion/exclusion criteria and 30-day dual antiplatelet therapy after percutaneous coronary in

52 An appropriate duration of dual antiplatelet therapy after percutaneous coronary in

53 discontinuation of the aspirin component of dual antiplatelet therapy after percutaneous coronary in

54 Dual antiplatelet therapy after percutaneous coronary in

55 t therapy with P2Y12 inhibitors alone versus dual-antiplatelet therapy after acute coronary syndromes

56 apy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain

57 patients received short-term (1 to 3 months) dual-antiplatelet therapy after the procedure and single

58 In the DAPT Study (Dual Antiplatelet Therapy), after percutaneous coronary

59 benefits and risks of 30 versus 12 months of dual antiplatelet therapy among patients undergoing coro

60 e is particularly high in patients receiving dual antiplatelet therapy and in the 1st year after stro

61 Continued dual antiplatelet therapy and optimal medical therapy (O

62 Dual antiplatelet therapy and periprocedural heparin sig

63 The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for

64 CH did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin mo

65 und -guided stenting, assiduous adherence to dual antiplatelet therapy, and adequate P2Y12 platelet r

66 Five patients had discontinued dual antiplatelet therapy, and in 3 of them discontinued

67 -angiotensin system blockers, beta-blockers, dual antiplatelet therapy, and long-term cardiovascular

68 urrent era of drug-eluting stents, prolonged dual antiplatelet therapy, and potent P2Y12 inhibitors a

69 nts received coronary revascularization, 22% dual-antiplatelet therapy, and 71% high-dose statin ther

70 tic event occurrences further solidified the dual antiplatelet therapy approach.

71 The effects of single- and dual-antiplatelet therapy are also assessed.

72 pirin in what has come to be commonly called dual antiplatelet therapy, are a mainstay of treatment f

73 /-7.9 years; 65% men; 75% diabetic) received dual antiplatelet therapy as a single loading dose (tica

74 Patients were randomized (1:1) to receive dual antiplatelet therapy (aspirin + clopidogrel [the cl

75 Total and premature discontinuation of dual antiplatelet therapy (aspirin and clopidogrel) is c

76 who received at least one coronary stent and dual antiplatelet therapy (aspirin and ticlopidine or cl

77 Dual antiplatelet therapy (aspirin plus a thienopyridine

78 al anticoagulation, empirical treatment with dual antiplatelet therapy (aspirin plus clopidogrel) for

79 ients with diabetes on long-term (12 months) dual antiplatelet therapy (aspirin plus clopidogrel) wer

80 Rates of dual antiplatelet therapy at 1 year were 32.2% for patie

81 ere (0.55%) or were not (0.52%) treated with dual antiplatelet therapy at hospital discharge (HR, 1.0

82 coronary intervention and were discharged on dual-antiplatelet therapy at 228 US hospitals in the Tre

83 ive patients treated with at least 1 BMS and dual antiplatelet therapy between 1994 and 2000.

84 ary stent implantation and were treated with dual antiplatelet therapy between July 1, 1994, and Apri

85 Dual antiplatelet therapy beyond 1 year after placement

86 atelet Therapy (DAPT) Study, continuation of dual antiplatelet therapy beyond 12 months after coronar

87 n of patient benefit and harm from continued dual antiplatelet therapy beyond assessment of MI histor

88 y outcome at 2 years was 10.1% with 24-month dual-antiplatelet therapy compared with 10.0% with 6-mon

89 atelets exhibit increased reactivity despite dual antiplatelet therapy, compared with smaller platele

90 ifornia) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months.

91 pite recent studies, the optimum duration of dual antiplatelet therapy (DAPT) after coronary drug-elu

92 The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting sten

93 The optimal duration of dual antiplatelet therapy (DAPT) after implantation of n

94 The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coro

95 the effect of 30 months versus 12 months of dual antiplatelet therapy (DAPT) after percutaneous coro

96 f ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coro

97 etes, use of drug-eluting stents, and use of dual antiplatelet therapy (DAPT) at randomization.

98 Although dual antiplatelet therapy (DAPT) beyond 1 year provides

99 luences the associations between patterns of dual antiplatelet therapy (DAPT) cessation and adverse e

100 Dual antiplatelet therapy (DAPT) cessation increases the

101 o determine the impact of baseline anemia on dual antiplatelet therapy (DAPT) cessation patterns <=2

102 The benefits and harms of dual antiplatelet therapy (DAPT) continuation beyond 1 y

103 Dual antiplatelet therapy (DAPT) de-escalation strategie

104 nhibitor monotherapy after a short course of dual antiplatelet therapy (DAPT) depends on the type of

105 pite medical guidelines recommending minimal dual antiplatelet therapy (DAPT) duration for patients w

106 spite treatment guidance endorsing shortened dual antiplatelet therapy (DAPT) duration in high bleedi

107 ercutaneous coronary intervention to 1-month dual antiplatelet therapy (DAPT) followed by 23-month ti

108 tion drug-eluting stent (DES), whether short dual antiplatelet therapy (DAPT) followed by single anti

109 have been validated in patients treated with dual antiplatelet therapy (DAPT) following percutaneous

110 current guidelines suggesting a benefit for dual antiplatelet therapy (DAPT) following peripheral va

111 The optimal duration of dual antiplatelet therapy (DAPT) following second-genera

112 Dual antiplatelet therapy (DAPT) for 12 months is the st

113 ant use of proton pump inhibitors (PPIs) and dual antiplatelet therapy (DAPT) for cardiovascular outc

114 Conventional dual antiplatelet therapy (DAPT) for patients with acute

115 Dual antiplatelet therapy (DAPT) has been the mainstay o

116 The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (

117 practice guidelines recommend post-operative dual antiplatelet therapy (DAPT) in patients who undergo

118 de updates regarding the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute

119 prolonged (24 months) vs short (</=6 months) dual antiplatelet therapy (DAPT) in patients with PAD un

120 Whether premature dual antiplatelet therapy (DAPT) interruption is safe in

121 Dual antiplatelet therapy (DAPT) is a class I guideline

122 Dual antiplatelet therapy (DAPT) is prescribed to millio

123 Prolonged dual antiplatelet therapy (DAPT) is recommended after ac

124 Prolonged dual antiplatelet therapy (DAPT) is recommended after an

125 Dual antiplatelet therapy (DAPT) is recommended for pati

126 Dual antiplatelet therapy (DAPT) is the standard approac

127 Outcomes with dual antiplatelet therapy (DAPT) or triple therapy (DAPT

128 Dual antiplatelet therapy (DAPT) reduced stroke risk in

129 Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with n

130 to short (6 months) versus long (24 months) dual antiplatelet therapy (DAPT) regimen.

131 among patients with DM participating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified

132 ndary analysis is derived from data from the Dual Antiplatelet Therapy (DAPT) Study, a multicenter tr

133 In the Dual Antiplatelet Therapy (DAPT) Study, continuation of

134 s recommend that these patients also receive dual antiplatelet therapy (DAPT) to reduce the risk of i

135 coagulation with a vitamin K antagonist plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor

136 Dual antiplatelet therapy (DAPT) with acetylsalicylic ac

137 Dual antiplatelet therapy (DAPT) with aspirin and a plat

138 Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y

139 Dual antiplatelet therapy (DAPT) with clopidogrel and as

140 Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 i

141 Dual antiplatelet therapy (DAPT), consisting of aspirin

142 (VKAs), single antiplatelet therapy (SAPT), dual antiplatelet therapy (DAPT), DOAC plus SAPT, VKA pl

143 , and clinical significance of bleeding with dual antiplatelet therapy (DAPT), particularly over an e

144 eated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment lea

145 intestinal (GI) events in patients requiring dual antiplatelet therapy (DAPT).

146 s 1, level of evidence A, recommendation for dual antiplatelet therapy (DAPT; aspirin plus clopidogre

147 Group 1, n=709); rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (DAPT; Group 2, n=709); and wa

148 The appropriate duration of dual-antiplatelet therapy (DAPT) after drug-eluting sten

149 The dual-antiplatelet therapy (DAPT) score was developed to

150 etal stents (BMS) under similar durations of dual-antiplatelet therapy (DAPT).

151 impact of an experimental strategy (1-month dual antiplatelet therapy [DAPT] followed by 23-month ti

152 telet therapy, and in 3 of them discontinued dual antiplatelet therapy discontinuation had occurred t

153 Dual antiplatelet therapy discontinuation seems to also

154 g PCI who have completed a 3-month course of dual antiplatelet therapy, discontinuation of aspirin fo

155 later-phase cardiovascular benefit of potent dual antiplatelet therapy driven largely by reducing de

156 drug-eluting stents, which require prolonged dual antiplatelet therapy due to the increased risk of l

157 ision tool (DAPT score) aids prescription of dual antiplatelet therapy duration in patients with or w

158 g late ischemic and bleeding risks to inform dual antiplatelet therapy duration showed modest accurac

159 er generation and BMS, thus allowing shorter dual antiplatelet therapy duration.

160 y (eg, with aspirin or a P2Y(12) inhibitor), dual antiplatelet therapy (eg, aspirin combined with a P

161 educed myocardial infarctions with prolonged dual antiplatelet therapy, findings that support the new

162 For patients on dual antiplatelet therapy followed for 1 year, the hazar

163 2Y12 inhibitor as monotherapy or to continue dual antiplatelet therapy for an additional 11 months.

164 In patients treated with dual antiplatelet therapy for at least 1 year after coro

165 These data support longer durations of dual antiplatelet therapy for patients receiving a stent

166 atients (Kaplan-Meier estimate, 5.5%) in the dual antiplatelet therapy group (absolute risk differenc

167 erapy group and in 21 patients (2.2%) in the dual antiplatelet therapy group (difference, -0.09 perce

168 onotherapy group and in 5.6% of those in the dual antiplatelet therapy group (hazard ratio, 0.46; 95%

169 712 in the monotherapy group and 1698 in the dual antiplatelet therapy group).

170 group 1, n=709); rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (group 2, n=709); and warfarin

171 therapy (group 2, n=709); and warfarin plus dual antiplatelet therapy (group 3, n=706).

172 However, dual antiplatelet therapy has been preliminarily associa

173 a P2Y(12) inhibitor after a short period of dual antiplatelet therapy has emerged as a bleeding redu

174 let therapy compared with 10.0% with 6-month dual-antiplatelet therapy (hazard ratio, 0.98; 95% confi

175 aspirin alone vs. 113 in the group receiving dual antiplatelet therapy) (hazard ratio, 1.52; 95% CI,

176 cing runs, earlier date of procedure, and no dual antiplatelet therapy; high pre-TAVR aortic peak gra

177 ere (0.71%) or were not (0.69%) treated with dual antiplatelet therapy (HR, 1.02; 95% CI, 0.54-1.95).

178 5, P=0.04), and premature discontinuation of dual antiplatelet therapy (HR=2.67, P=0.003); high plate

179 olled trials are needed to establish whether dual antiplatelet therapy improves clinical outcome in h

180 eeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery dis

181 x vivo platelet aggregation before and after dual antiplatelet therapy in individuals (n=565) from th

182 -based therapy was superior to warfarin plus dual antiplatelet therapy in lowering bleeding outcomes

183 Dual antiplatelet therapy in older versus younger patien

184 udy was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocard

185 tion could be associated with high RPR after dual antiplatelet therapy in patients with stable corona

186 Evidence for efficacy of dual antiplatelet therapy in stroke is limited.

187 ed the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient

188 ScTs occurred in patients who had suspended dual antiplatelet therapy, in 6 cases prematurely.

189 f increased use of clopidogrel, statins, and dual antiplatelet therapy, in addition to the introducti

190 with aspirin, we aimed to establish whether dual antiplatelet therapy involving cilostazol is safe a

191 esidual platelet reactivity (high RPR) after dual antiplatelet therapy is associated with increased c

192 ed early after stenting, and particularly if dual antiplatelet therapy is discontinued.

193 ts with drug-eluting stents, especially when dual antiplatelet therapy is interrupted.

194 In case of coronary intervention, temporary dual antiplatelet therapy is mandatory as well.

195 Dual antiplatelet therapy is recommended after coronary

196 Although dual antiplatelet therapy is recommended, single antipla

197 coated with biolimus-A9 followed by 1-month dual antiplatelet therapy is safer and more effective th

198 whether OMT modifies the treatment effect of dual antiplatelet therapy is unknown.

199 However, long-term dual-antiplatelet therapy is linked to higher risk for I

200 ed events while patients received background dual antiplatelet therapies (ITT: 7.9% vs. 11.9%, p = 0.

201 tion of DAPT after the procedure, and longer dual antiplatelet therapy (L-DAPT) was defined as the pe

202 Compared with monotherapy, dual-antiplatelet therapy lasting more than 1 year after

203 ompared with aspirin alone or short duration dual antiplatelet therapy (</=6 months), continued treat

204 studies suggest that early administration of dual antiplatelet therapy may be better than monotherapy

205 The benefits and risks of prolonged dual antiplatelet therapy may be different for patients

206 ntial for shortening the minimum duration of dual antiplatelet therapy needed after coronary interven

207 ective comparison of the current standard of dual antiplatelet therapy of aspirin with clopidogrel ve

208 ed to assess the effect of extended duration dual antiplatelet therapy on mortality by doing a meta-a

209 2 observational studies suggest a benefit of dual antiplatelet therapy on overall survival and amputa

210 with extended duration versus short duration dual antiplatelet therapy or aspirin alone.

211 ommonly used agent, in higher-risk patients, dual antiplatelet therapy or combining antiplatelet ther

212 therapy with more potent antiplatelet drugs, dual antiplatelet therapy, or vitamin K antagonists furt

213 Among patients at HBR with abbreviated dual antiplatelet therapy post-stenting, the use of an u

214 ding, lower serum albumin, and preprocedural dual antiplatelet therapy; procedural variables included

215 mostly been studied in addition to aspirin; dual-antiplatelet therapy proved superiority compared wi

216 xtended duration versus no or short duration dual antiplatelet therapy, published before Oct 1, 2014.

217 ared with 12 months of therapy, 30 months of dual antiplatelet therapy reduced the risk of stent thro

218 s with critical limb ischemia, perioperative dual antiplatelet therapy reduces biomarkers of atheroth

219 Dual antiplatelet therapy reduces ischemic events in car

220 The management of the dual antiplatelet therapy regimen should be customized t

221 Dual antiplatelet therapy remains the cornerstone of med

222 0 person-years for TT, VKA+antiplatelet, and dual antiplatelet therapy, respectively.

223 tensin receptor blockers, beta-blockers, and dual antiplatelet therapy, respectively.

224 R1) gene to be most strongly associated with dual antiplatelet therapy response (P=7.66x10(-9)).

225 ions of DAPT after DES implantation: shorter dual antiplatelet therapy (S-DAPT) was defined as the pe

226 Dual antiplatelet therapy significantly reduced risk of

227 ing events mostly occurred within the 21-day dual antiplatelet therapy stage and were generally mild.

228 New data from long-term dual antiplatelet therapy studies and investigations of

229 aclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12

230 (The Dual Antiplatelet Therapy Study [DAPT Study]; NCT0097793

231 The Dual Antiplatelet Therapy Study is large streamlined cli

232 The Dual Antiplatelet Therapy Study, a randomized double-bli

233 Within the Dual Antiplatelet Therapy Study, clinical trial sites ha

234 articipating versus not participating in the Dual Antiplatelet Therapy Study.

235 ls, of which 309 (24.2%) participated in the Dual Antiplatelet Therapy Study.

236 (The Dual Antiplatelet Therapy Study; NCT00977938).

237 The DAPT (Dual Antiplatelet Therapy) study enrolled patients after

238 The DAPT (Dual Antiplatelet Therapy) Study, a double-blind trial,

239 2]) but was greater among patients receiving dual-antiplatelet therapy than among those receiving clo

240 Among stented patients who were treated with dual antiplatelet therapy, there was a mortality reducti

241 Patients in trials evaluating stents or dual antiplatelet therapy to prevent coronary stent thro

242 mly assigned patients with an indication for dual antiplatelet therapy to receive clopidogrel in comb

243 g would represent a paradigm shift away from dual antiplatelet therapy toward long-term triple antith

244 ntation Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy) trial was a 1:1 randomized, m

245 Dual antiplatelet therapy until surgery is beneficial, w

246 Meta-analysis of dual antiplatelet therapy versus monotherapy with P2Y12

247 fatal hemorrhages (9 in the group receiving dual antiplatelet therapy vs. 4 in the group receiving a

248 with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months f

249 Extended duration dual antiplatelet therapy was not associated with a diff

250 Dual antiplatelet therapy was prescribed for 6 months.

251 icoagulation with warfarin, as compared with dual antiplatelet therapy, was associated with a decreas

252 agulation (both NOACs and warfarin), but not dual antiplatelet therapy, was effective in prevention o

253 ization, and patients with an indication for dual antiplatelet therapy were excluded.

254 T2DM patients on chronic dual antiplatelet therapy were screened to identify subo

255 botic therapy (ie, oral anticoagulation plus dual antiplatelet therapy) were independent predictors o

256 -positive patients were planned for 12-month dual antiplatelet therapy, whereas troponin-negative pat

257 Indeed, dual antiplatelet therapy, which has been found to be be

258 ention, but their use necessitates prolonged dual antiplatelet therapy, which increases costs and ble

259 res are performed annually in the U.S., with dual-antiplatelet therapy, which includes the use of bot

260 peratively (days 5 and 2) despite continuing dual antiplatelet therapy while undergoing multidigit re

261 The observation that dual antiplatelet therapy with acetylsalicylic acid and

262 ted heparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) an

263 Dual antiplatelet therapy with aspirin and a P2Y(12) inh

264 Dual antiplatelet therapy with aspirin and a P2Y12 inhib

265 Dual antiplatelet therapy with aspirin and a P2Y12 inhib

266 BACKGROUND- Aspirin or dual antiplatelet therapy with aspirin and clopidogrel i

267 Dual antiplatelet therapy with aspirin and clopidogrel i

268 The effects of dual antiplatelet therapy with aspirin and clopidogrel o

269 Although dual antiplatelet therapy with aspirin and clopidogrel r

270 stent (DES) implantation require additional dual antiplatelet therapy with aspirin and clopidogrel.

271 )+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel.

272 Dual antiplatelet therapy with clopidogrel plus aspirin

273 appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus aspirin.

274 Dual antiplatelet therapy with clopidogrel plus low-dose

275 patients, the median duration of concomitant dual antiplatelet therapy with clopidogrel treatment was

276 med a post hoc analysis of the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAP

277 The Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAP

278 Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAP

279 n the large-scale, prospective Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents study

280 rolled in the ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) acco

281 as performed in the ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) regi

282 The prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) stud

283 ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was

284 METHODS AND ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was

285 ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was

286 , multicenter ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) were

287 es (PROMETHEUS, ADAPT-DES [the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents], THI

288 on and had subsequently completed 1 month of dual antiplatelet therapy with no ischemic or major blee

289 The optimal duration of dual antiplatelet therapy with prasugrel after TAXUS Lib

290 notherapy was not found to be noninferior to dual antiplatelet therapy with respect to a composite of

291 tor monotherapy was noninferior to continued dual antiplatelet therapy with respect to the occurrence

292 However, the optimal duration of dual antiplatelet therapy with specific types of drug-el

293 lementation after loading and maintenance of dual antiplatelet therapy with ticagrelor and the influe

294 Dual antiplatelet therapy with ticlopidine and aspirin i

295 Dual-antiplatelet therapy with aspirin and a thienopyrid

296 Dual-antiplatelet therapy with aspirin and clopidogrel a

297 coronary syndromes who were mostly receiving dual antiplatelet therapy, with conflicting results on e

298 vascularization and had completed 1 month of dual antiplatelet therapy without complications, P2Y12-i

299 ne coronary stenting and completed 1 year of dual antiplatelet therapy without major bleeding or isch

300 We hypothesized that perioperative dual antiplatelet therapy would improve biomarkers of at